story of the week
Everolimus vs Sunitinib for Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
Everolimus Versus Sunitinib for Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN): A Multicentre, Open-Label, Randomised Phase 2 Trial
Lancet Oncol 2016 Jan 12;[EPub Ahead of Print], AJ Armstrong, S Halabi, T Eisen, et alRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.